Seeing through the challenges of ocular allergy: Optimization of diagnosis and treatment strategies
Activity Description / Statement of Need:
In this online, self-learning activity:
Ocular allergy (OA), also known as allergic eye disease, is an ocular surface hypersensitivity disorder resulting from an abnormal immunologic response of the eye to various antigens. It is not a single clinical entity, rather it includes the following conditions with differing hypersensitivity mechanisms, diagnostic criteria, pathogenesis, and management strategies: seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis, giant papillary conjunctivitis, and contact dermatoconjunctivitis. OA affects approximately 40% of the global population, with SAC and PAC specifically affecting 15 to 25%. Ocular itch associated with SAC and PAC is the hallmark symptom of the disease. The multifactorial dimensions of OA contribute to economic ramifications in the United States (US) estimated at $2 billion annually in prescriptions, with the costs associated with over-the-counter (OTC) medications projected to be tenfold higher than prescription sales.
Target Audience:
The following HCPs: ophthalmologists, allergists, and general practitioners; physician assistants and nurse practitioners in the aforementioned areas of specialty; and any other clinicians involved or interested in the treatment of ocular allergy.
Cost: Free
View Offer chevron_rightDetails
Activity Description / Statement of Need:
In this online, self-learning activity:
Ocular allergy (OA), also known as allergic eye disease, is an ocular surface hypersensitivity disorder resulting from an abnormal immunologic response of the eye to various antigens. It is not a single clinical entity, rather it includes the following conditions with differing hypersensitivity mechanisms, diagnostic criteria, pathogenesis, and management strategies: seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis, giant papillary conjunctivitis, and contact dermatoconjunctivitis. OA affects approximately 40% of the global population, with SAC and PAC specifically affecting 15 to 25%. Ocular itch associated with SAC and PAC is the hallmark symptom of the disease. The multifactorial dimensions of OA contribute to economic ramifications in the United States (US) estimated at $2 billion annually in prescriptions, with the costs associated with over-the-counter (OTC) medications projected to be tenfold higher than prescription sales.
Target Audience:
The following HCPs: ophthalmologists, allergists, and general practitioners; physician assistants and nurse practitioners in the aforementioned areas of specialty; and any other clinicians involved or interested in the treatment of ocular allergy.